FAIRTOP: Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain
Study Details
Study Description
Brief Summary
Assess whether transbuccal fentanyl provides more rapid relief of orthopedic pain, than does the comparator Percocet
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1/Phase 2 |
Detailed Description
Patients will be initially deemed eligible for study consideration if, after MGH ED nursing triage, an X-ray is ordered for suspected isolated extremity injury and the triage acuity level is "Minor". Study staff (physicians) will monitor the ED registration and triage areas to assess whether triaged patients are potentially eligible.
For ED patients with minor isolated injuries, X-rays are often ordered from triage, where there is a supervising physician (or nurse practitioner) available to examine patients and direct care. Either at triage (for patients undergoing care at that location) or when patients are moved to the ED's Minor Surgery area, the supervising healthcare provider will be approached immediately after that individual's evaluation of the patient, and before any pain medication is administered, to begin the process of eligibility ascertainment.
If the provider agrees that the patient may be a candidate for the study, the next step will be for the provider to ask the patient if study staff may approach to discuss the trial.
If the patient agrees to have study staff approach to discuss the trial, study personnel (all EM resident or Attending-level physicians) will be introduced by healthcare providers to potential subjects. Study staff will then converse with the patients about the study's aims, methodology, and risks, confirming eligibility and determining if patients will consent to participate.
Patients who are approached, but who are determined to be ineligible, will have no data recorded, other than their age and race/ethnicity and the reason they were ineligible.
If eligible patients provide written consent in the manner and form dictated by Partners guidelines, the study procedures will commence.
For eligible patients who do not give consent, study physicians will emphasize that patient care will be unaffected by their decision. No further contact will occur between study staff and those patients. No identifying information about such patients will be recorded, but their age and race/ethnicity will be recorded. (Recording this information will allow for subsequent assessment for selection bias, and will also help search for patterns in patient types refusing analgesia trial participation.)
The actual medication administration will involve the following steps:
-
Patients participating in the study will be identified and placed in a "room" (stretcher or actual ED room) in the MGH ED's Minor Multipurpose (MIMP) area;
-
RNs will obtain the study medication pairs (buccal tablet + oral tablet) from the computerized medication storage area - RNs will take the next-numbered medication pair from the MGH Research Pharmacy-prepared drug packaging;
-
Actual medications will be administered by a licensed physician (a study co-investigator, EM resident or Attending physician at MGH), who is not the co-investigator monitoring the patient for endpoint assessment - the physician administering the medication/placebo will inform neither the patient nor the clinical or study staff, the identity of the medication/placebo pair given.
Patients will be monitored by a study physician co-investigator physically present with the patient, for a total of 120 minutes after administration of medication. They will be asked q-5-minutes, through 60 minutes, to rate their pain and degree of nausea, as well as to describe any adverse reactions to the medication. Both pain and nausea levels will be recorded using 10-point scales. Use of such scales is common in the pain literature, and is an emerging tool for evaluation of nausea.1,2 Data collection for analgesia efficacy will cease after 60 minutes, but patients will be monitored for at least another 60 minutes to maximize safety; patients will be assessed for discharge suitability by treating clinicians/nurses in the same fashion as other ED patients who receive opioids.
Vital signs (respiratory rate, blood pressure, heart rate, pulse oximetry) will be monitored for the two hours of the study. Continuous pulse oximetry will be used during the first study hour, and q5-minute spot-check pulse oximetry will be used during the second study hour; pulse oximetry monitoring will be changed to continuous mode during the second study hour if any spot-check reading falls below 98%. Other (non-pulse oximetry) vital signs will be monitored q5-minutes during the first study hour, and q15-minutes during the second study hour. These vital signs monitoring parameters represent the minimum for study subjects; treating clinicians or study staff physicians can increase the frequency of vital signs monitoring at their discretion. Any study subject not admitted to the hospital, will be discharged under the care of a responsible adult.
At the conclusion of the data collection period, patients will be asked if they would want to receive the same medication in the future. Other than a 24-hour telephone call (made only if patients agree), intended to assess for delayed problems such as nausea/vomiting, there will be no other study procedures or interventions.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Arm 1 / Fentora Intervention Group: Subject receives: placebo oral/swallowed pill Fentanyl (Fentora) 100mcg rapidly dissolving transbuccal tablet |
Drug: Fentanyl
Fentanyl rapid dissolving tablet 100mcg
Other Names:
|
| Active Comparator: Arm 2 / Percocet/Prevacid Active Comparator Group: Subject receives: Oxycodone/APAP (Percocet) 5/325 mg oral/swallowed pill Lansoprazole 15 mg (Prevacid) comparator rapidly dissolving transbuccal tablet |
Drug: Lansoprazole
lansoprazole 15mg rapidly dissolving tablet
Other Names:
Drug: Oxycodone
Oxycodone 5/325 mg tablet
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Time to Analgesia [60 minutes]
Time it took for subjects to achieve a pain score reduction of 2 units (on a 0 to 10 scale)
- Pain Reduction [60 minutes]
Number of subjects who reached pain reduction. A subject was deemed to have reached pain reduction if there was a two-point drop in pain scale (0-10).
Secondary Outcome Measures
- Occurrence of Untoward Opioid Side Effects [120 minutes]
Subjects were monitored for any signs of untoward opioid side effects.
Eligibility Criteria
Criteria
INCLUSION:
-
18-60 years of age
-
Present to ED with a chief complaint of extremity injury
-
Negative pregnancy test (urine or blood)
-
Clinician judges subject to need extremity radiography to rule out a fracture
-
Subjects must indicate that their pain is of sufficient severity to warrant treatment with a pain medication stronger than acetaminophen or aspirin.
-
Subject's treating ED provider is aware of, and approves, participation (i.e. participation cannot be allowed to impair provision of standard patient care).
EXCLUSION:
-
Treating provider judges that IV analgesia is required
-
Allergy to acetaminophen or to any opiate/opioid
-
Currently taking phenothiazines or CNS depressants (including alcohol), or if subject has taken MAO inhibitors or SSRIs within the past two weeks
-
Already taken or been administered opioid analgesia for their current injury
-
Chronic opioid therapy or if the subject (or their medical records) indicate a history of opioid abuse
-
Breastfeeding mothers
-
If subject is planning to drive home after their ED visit, or if they are judged for any other reason to be non-candidates for opioid therapy.
-
hypersensitivity to lansoprazole
-
phenylketonuria
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Massachusetts General Hospital | Boston | Massachusetts | United States | 02114 |
Sponsors and Collaborators
- Massachusetts General Hospital
Investigators
- Principal Investigator: Stephen H Thomas, MD, MPH, Massachusetts General Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- FAIRTOP
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Arm 1 / Fentora | Arm 2 / Percocet/Prevacid |
|---|---|---|
| Arm/Group Description | Subject receives placebo swallowed pill, and Fentora 100mcg rapidly dissolving transbuccal tablet | Subject receives Percocet swallowed pill, and Prevacid comparator rapidly dissolving transbuccal tablet |
| Period Title: Overall Study | ||
| STARTED | 30 | 30 |
| COMPLETED | 30 | 30 |
| NOT COMPLETED | 0 | 0 |
Baseline Characteristics
| Arm/Group Title | Arm 1 / Fentora | Arm 2 / Percocet/Prevacid | Total |
|---|---|---|---|
| Arm/Group Description | Subject receives placebo swallowed pill, and Fentora 100mcg rapidly dissolving transbuccal tablet | Subject receives Percocet swallowed pill, and Prevacid comparator rapidly dissolving transbuccal tablet | Total of all reporting groups |
| Overall Participants | 30 | 30 | 60 |
| Age (Count of Participants) | |||
| <=18 years |
0
0%
|
0
0%
|
0
0%
|
| Between 18 and 65 years |
30
100%
|
30
100%
|
60
100%
|
| >=65 years |
0
0%
|
0
0%
|
0
0%
|
| Age (years) [Mean (Standard Deviation) ] | |||
| Mean (Standard Deviation) [years] |
29
(8)
|
30
(12)
|
30
(10)
|
| Gender (Count of Participants) | |||
| Female |
10
33.3%
|
12
40%
|
22
36.7%
|
| Male |
20
66.7%
|
18
60%
|
38
63.3%
|
| Region of Enrollment (participants) [Number] | |||
| United States |
30
100%
|
30
100%
|
60.0
100%
|
Outcome Measures
| Title | Time to Analgesia |
|---|---|
| Description | Time it took for subjects to achieve a pain score reduction of 2 units (on a 0 to 10 scale) |
| Time Frame | 60 minutes |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Arm 1 / Fentora | Arm 2 / Percocet/Prevacid |
|---|---|---|
| Arm/Group Description | Subject receives placebo swallowed pill, and Fentora 100mcg rapidly dissolving transbuccal tablet | Subject receives Percocet swallowed pill, and Prevacid comparator rapidly dissolving transbuccal tablet |
| Measure Participants | 30 | 30 |
| Median (Inter-Quartile Range) [minutes] |
10
|
35
|
| Title | Pain Reduction |
|---|---|
| Description | Number of subjects who reached pain reduction. A subject was deemed to have reached pain reduction if there was a two-point drop in pain scale (0-10). |
| Time Frame | 60 minutes |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Arm 1 / Fentora | Arm 2 / Percocet/Prevacid |
|---|---|---|
| Arm/Group Description | Subject receives placebo swallowed pill, and Fentora 100mcg rapidly dissolving transbuccal tablet | Subject receives Percocet swallowed pill, and Prevacid comparator rapidly dissolving transbuccal tablet |
| Measure Participants | 30 | 30 |
| Count of Participants [Participants] |
30
100%
|
24
80%
|
| Title | Occurrence of Untoward Opioid Side Effects |
|---|---|
| Description | Subjects were monitored for any signs of untoward opioid side effects. |
| Time Frame | 120 minutes |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Arm 1 / Fentora | Arm 2 / Percocet/Prevacid |
|---|---|---|
| Arm/Group Description | Intervention Group: Subject receives: placebo oral/swallowed pill Fentanyl (Fentora) 100mcg rapidly dissolving transbuccal tablet Fentanyl: Fentanyl rapid dissolving tablet 100mcg | Active Comparator Group: Subject receives: Oxycodone/APAP (Percocet) 5/325 mg oral/swallowed pill Lansoprazole 15 mg (Prevacid) comparator rapidly dissolving transbuccal tablet Lansoprazole: lansoprazole 15mg rapidly dissolving tablet Oxycodone: Oxycodone 5/325 mg tablet |
| Measure Participants | 30 | 30 |
| Count of Participants [Participants] |
0
0%
|
1
3.3%
|
Adverse Events
| Time Frame | 1 day after enrollment, subjects were contacted | |||
|---|---|---|---|---|
| Adverse Event Reporting Description | ||||
| Arm/Group Title | Arm 1 / Fentora | Arm 2 / Percocet/Prevacid | ||
| Arm/Group Description | Subject receives placebo swallowed pill, and Fentora 100mcg rapidly dissolving transbuccal tablet | Subject receives Percocet swallowed pill, and Prevacid comparator rapidly dissolving transbuccal tablet | ||
All Cause Mortality |
||||
| Arm 1 / Fentora | Arm 2 / Percocet/Prevacid | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | / (NaN) | / (NaN) | ||
Serious Adverse Events |
||||
| Arm 1 / Fentora | Arm 2 / Percocet/Prevacid | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/30 (0%) | 0/30 (0%) | ||
Other (Not Including Serious) Adverse Events |
||||
| Arm 1 / Fentora | Arm 2 / Percocet/Prevacid | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/30 (0%) | 0/30 (0%) | ||
Limitations/Caveats
More Information
Certain Agreements
All Principal Investigators ARE employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Stephen Thomas |
|---|---|
| Organization | Harvard/MGH |
| Phone | 6177267622 |
| sthomasmd@gmail.com |
- FAIRTOP